Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Purchases of Investments

Cash used to buy marketable securities and other investments.

Tango Therapeutics, Inc.NASDAQ: TNGX

Purchases of Investments · Q3 FY2026 · quarter ended Sep 2026

Purchases of investments growth accelerates

Q3 FY2026 purchases of investments of $301.49M (cash outflow) rose 1544.1% year over year, ahead of the +760.8% change in trailing-twelve-month purchases of investments. Sequentially, it fell 41.9% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Purchases of investments amounted to 423.9% of revenue in FY2025, down 148.7 pp from a year earlier.
  • Purchases of investments grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1544.1% holds above the trailing-twelve-month pace of +760.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$301.49M-41.9% QoQ
Last fiscal yearDec 2025
-$264.46M+9.8% YoY
LTMSep 2026
-$1.05B+760.8% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1544.1%——
1 year+9.8%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(264.46M) USD
Year-over-year change
-9.8%

Purchases of Investments vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's LTM Sep 2026 purchases of investments of $1.05B is the 2nd largest of the 11 companies compared; the peer median is $393.77M.
  • Its year-over-year change of +760.8% is the highest of 11, against a peer median of +12.0%.
  • Over three fiscal years its annual growth of +8.2% compares with a peer median of -2.1%.
TNGX Competitors Peer median
Purchases of Investments for TNGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$3B +43.1%+43.1%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$1.05B +760.8%+8.2%—
ERASErasca, Inc.LTM Sep 2026$820.26M +366.4%+4.0%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$614.3M +65.5%-38.8%5935.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$604.34M +4.3%+23.9%86.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$545.29M -33.6%+33.4%242.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$242.25M +19.8%+1.1%694.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$147.06M -47.7%-31.6%521.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$91.4M +61.3%-5.4%546.7%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$78.36M -59.8%-18.4%—
NUVBNuvation Bio Inc.LTM Jun 2026$7.46M -97.1%-12.0%4.4%
Peer median (excluding TNGX) $393.77M+12.0%-2.1%521.0%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
Deferred Income Tax00000
Stock-Based Compensation7.83M14.23M19.08M28.9M26.43M
Change in Working Capital(11.35M)(18.49M)(37.97M)(31.75M)(67.2M)
Accounts Receivables002M00
Inventory00000
Accounts Payables1.23M1.1M(1.71M)(1.18M)(825K)
Other Working Capital(12.58M)(19.59M)(38.26M)(30.56M)(66.37M)
Other Non-Cash Items1.32M1.75M234K(849K)1.2M
Operating Cash Flow(59.53M)(109.08M)(117.98M)(131.5M)(138.89M)
Capital Expenditures(1.84M)(7.69M)(1.53M)(754K)(1.05M)
Acquisitions (Net)00000
Purchases of Investments(372.36M)(208.5M)(310.57M)(240.89M)(264.46M)
Sales of Investments190.76M242.6M353.53M327.77M224.64M
Other Investing Activities00000
Investing Cash Flow(183.43M)26.4M41.43M86.13M(40.87M)
Debt Repayment342.11M0000
Common Stock Issued0080.02M41.72M222.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(14.78M)1.62M2.39M5.94M(36K)
Financing Cash Flow357.33M1.62M82.41M47.66M222.5M
Effect of Forex Changes00000
Net Change in Cash114.36M(81.07M)5.85M2.29M42.75M
Free Cash Flow(61.36M)(116.77M)(119.51M)(132.26M)(139.93M)

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.